PT - JOURNAL ARTICLE AU - Polonsky, Jonathan A. AU - Böhning, Dankmar AU - Keita, Mory AU - Ahuka-Mundeke, Steve AU - Nsio-Mbeta, Justus AU - Abedi, Aaron Aruna AU - Mossoko, Mathias AU - Estill, Janne AU - Keiser, Olivia AU - Kaiser, Laurent AU - Yoti, Zabulon AU - Sangnawakij, Patarawan AU - Lerdsuwansri, Rattana AU - Rio Vilas, Victor J. Del TI - Novel application of capture-recapture methods to estimate the completeness of contact tracing during a large outbreak of Ebola Virus Disease, Democratic Republic of Congo, 2018-2020 AID - 10.1101/2021.05.18.21257407 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.18.21257407 4099 - http://medrxiv.org/content/early/2021/05/20/2021.05.18.21257407.short 4100 - http://medrxiv.org/content/early/2021/05/20/2021.05.18.21257407.full AB - Despite its critical role in containing outbreaks, the efficacy of contact tracing (CT), measured as the sensitivity of case detection, remains an elusive metric. We estimated the sensitivity of CT by applying unilist capture-recapture methods on data from the 2018-2020 outbreak of Ebola virus disease in the Democratic Republic of Congo. We applied different distributional assumptions to the zero-truncated count data to estimate the number of unobserved cases with a) any contacts and b) infected contacts, to compute CT sensitivity. Geometric distributions were the best fitting models. Our results indicate that CT efforts identified almost all (n=792, 99%) of the cases with any contacts, but only half (n=207, 48%) of the cases with infected contacts, suggesting that CT efforts performed well at identifying contacts during the listing stage, but performed poorly during the contact follow-up stage. We discuss extensions to our work and potential applications for the current COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comité d'éthique de l'Ecole de Santé Publique de l'Université of Kinshasa (DRC) reference: ESP/CE/03/2021All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analysed during the current study are not publicly available due to patient confidentiality concerns, but are available from the corresponding author on reasonable request.